Russia prepares for drug shortage in coming years

13 May 2019
russia_li

The existing sanctions regime against Russia may lead to the shortage of drugs in the local market over the next several years, according to recent statements by analysts of the Russian Ministry of Health and some local experts in the field of pharmaceuticals, reports The Pharma Letter’s local correspondent.

According to these experts, due to sanctions, the number of applications submitted by Western drug producers to the Russian Federal Patent Service (Rospatent) and other regulatory bodies for the registration of their inventions, particularly drugs, has significantly declined in recent years.

This is reflected by the official statistics of the Russian Federal Customs Service, according to which drug imports from the USA and the European Union to Russia continued to decline this year, compared to the same period for the beginning of 2018.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical